E-cigarette exposure disrupts antitumor immunity and promotes metastasis

Front Immunol. 2024 Aug 16:15:1444020. doi: 10.3389/fimmu.2024.1444020. eCollection 2024.

Abstract

Electronic cigarettes (e-cigarettes) are thought to pose low risk of cancer because the components of e-cigarette liquid are not carcinogens. We analyzed the effects of the two major components, PG/VG and nicotine, on tumor development in preclinical models. We found that PG/VG promoted tumor cell migration in migration assays and contributed to more aggressive, metastatic, and immunosuppressive tumors in vivo, aggravated by the presence of nicotine. Whole body exposure of mice to PG/VG and nicotine rendered animals more susceptible to developing tumors with high frequencies of infiltrating proinflammatory macrophages expressing IL-6 and TNFα. Moreover, tumor-infiltrating and circulating T cells in e-cigarette exposed mice showed increased levels of immune checkpoints including CTLA4 and PD-1. Treatment with anti-CTLA4 antibody was able to abrogate metastasis with no detrimental effects on its ability to induce tumor regression in exposed mice. These findings suggest that the major components used in e-cigarette fluid can impact tumor development through induced immunosuppression.

Keywords: electronic cigarettes; immune checkpoint blockade; immunosuppression; metastasis; whole body exposure.

MeSH terms

  • Animals
  • CTLA-4 Antigen / immunology
  • Cell Line, Tumor
  • Cell Movement / drug effects
  • Electronic Nicotine Delivery Systems*
  • Female
  • Mice
  • Mice, Inbred C57BL
  • Neoplasm Metastasis
  • Nicotine*
  • Programmed Cell Death 1 Receptor

Substances

  • Nicotine
  • CTLA-4 Antigen
  • Ctla4 protein, mouse
  • Programmed Cell Death 1 Receptor

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was funded in part by cooperative agreement U54HL147127 from the National Heart, Lung, and Blood Institute and the Food and Drug Administration Center for Tobacco Products and the UCSF Cancer Center, the DRC Center Grant NIH P30 DK063720, and NIH grant R35CA253175. We thank the UCSF TCORS working group for valuable feedback and discussion. We thank Mike Klodnicki for assistance in mounting and servicing the Gram vaping machine.